Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
Conditions
Keywords
vaccine, lung, cancer, Carcinoma, Large Cell, Non-Small-Cell Lung Carcinoma
Brief summary
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Non-Small Cell Lung Cancer.
Interventions
BIOLOGICALEP2101
Sponsors
Epimmune
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa * At least four weeks following prior standard treatment, with no evidence of disease * Must use adequate birth control
Exclusion criteria
* Prior cancer vaccine therapy or concurrent participation in any other investigational study * A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment * A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine * Women who are pregnant, intend to become pregnant, or who are breast feeding
Countries
United States
Outcome results
None listed